Dr. Jonathan R. Isaacson, MD
Neurology (Neurology Physician)
At a glance
- Years since graduation
- 7
- In the NPI registry since
- 2019
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 319274 · FL license 158625 · MA license 295358 · NC license 2025-02971 · OR license MD225638 · TN license 74081 · VA license 0101281694 · WA license MD61687498 · WI license 13560-320
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health Matthews Medical Center Matthews, NC
- Johnston Memorial Hospital Abingdon, VA
- Greeneville Community Hospital Greeneville, TN
Medical groups
- Novant Health Medical Group, LLC (2,430 clinicians)
- Wellmont Medical Associates Inc (433 clinicians)
- Stuart H. Isaacson, M.d, P.a. (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in New York, NY | 62 |
| Fludrocortisone Acetate Other prescribers in New York, NY | 48 |
| Midodrine Hcl Other prescribers in New York, NY | 26 |
| Droxidopa | 19 |
| Rivastigmine Other prescribers in New York, NY | 17 |
| Gabapentin Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 29 payments worth $1,795 in total to this clinician.
| Amneal Pharmaceuticals LLC | $1,417 |
|---|---|
| Merz Pharmaceuticals, LLC | $97.60 |
| Teva Pharmaceuticals USA, Inc. | $88.41 |
| AbbVie Inc. | $62.43 |
| Neurocrine Biosciences, Inc. | $44.21 |
| Boston Scientific Corporation | $35.20 |
| Biogen, Inc. | $29.27 |
| Eisai Inc. | $21.39 |
| Consulting Fee | $1,225 |
|---|---|
| Food and Beverage | $570 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amneal Pharmaceuticals LLC Jun 26, 2025 | Consulting Fee CREXONT · NEUROLOGY | $1,225 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,093 in research payments for these studies, mostly to the institutions running them.
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT)
H. Lundbeck A S
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.